Skip to content
The Nexus
DossierENTITY

Avalyn Pharma Inc.

Coverage of Avalyn Pharma Inc. in the Nexus archive.

Earliest in view: Apr 30 · 16:36 UTCMost recent: Jun 3 · 12:10 UTC
Co-mentioned in this coverage
Bostonplace1Automated Insightsorganization1Zacks Investment Researchorganization1AVLNtopic1Novoorganization1Lyn Baranowskiperson1Nasdaq MarketSiteplace1New Yorkplace1USplace1biopharmatopic1rare lung diseasestopic1
Recent coverage
  • BUSINESSJun 3 · 12:10 UTCWTOP DC
    Avalyn: Q1 Earnings Snapshot

    Avalyn Pharma Inc. reported a $26.9 million loss in its first quarter, equivalent to $21.83 per share. The Boston-based company's earnings snapshot was generated by Automated Insights using data from Zacks Investment Research.

  • BUSINESSApr 30 · 16:36 UTCBLOOMBERG
    Novo-Backed Drugmaker Avalyn Soars 44% After $300 Million US IPO

    Avalyn Pharma Inc., a biopharma company developing inhaled treatments for rare lung diseases, raised $300 million in a US initial public offering that priced at the top of its marketed range. The stock surged 44% on its first day of trading, with CEO Lyn Baranowski ringing the opening bell at Nasdaq MarketSite in New York.

Avalyn Pharma Inc. · Dossier · The Nexus